Thalidomide in induction treatment increases the very good partial response rate before and after high-dose therapy in previously untreated multiple myeloma

Haematologica. 2008 Jan;93(1):124-7. doi: 10.3324/haematol.11644.

Abstract

In the prospective phase 3 HOVON-50/GMMG-HD3 trial, patients randomized to TAD (thalidomide, doxorubicin, dexamethasone) had a significantly higher response rate (at least PR) after induction compared with patients randomized to VAD (vincristine, adriamycin, dexamethasone, 72% vs. 54%, p<0.001). Complete remission (CR) and very good partial remission (VGPR) were also higher after TAD. After High Dose melphalan 200mg/m(2) response was comparable in both arms, 76% and 79% respectively. However, CR plus VGPR were significantly higher in the patients randomized to TAD (49% vs. 32%, p<0.001). CTC grade 3-4 adverse events were similar in both arms.

Publication types

  • Clinical Trial, Phase III
  • Randomized Controlled Trial

MeSH terms

  • Adult
  • Aged
  • Angiogenesis Inhibitors / therapeutic use
  • Antineoplastic Combined Chemotherapy Protocols / administration & dosage
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Cytarabine / therapeutic use
  • Daunorubicin / therapeutic use
  • Dexamethasone / therapeutic use
  • Female
  • Humans
  • Male
  • Medical Oncology / methods*
  • Middle Aged
  • Multiple Myeloma / drug therapy*
  • Remission Induction
  • Thalidomide / therapeutic use*
  • Thioguanine / therapeutic use
  • Treatment Outcome
  • Vincristine / therapeutic use

Substances

  • Angiogenesis Inhibitors
  • Cytarabine
  • Thalidomide
  • Vincristine
  • Dexamethasone
  • Thioguanine
  • Daunorubicin

Supplementary concepts

  • DAT protocol 1
  • VAD regimen